Introduction
Gastric cancer remains as one of the major causes of death from cancer worldwide. Despite a markedly improved survival trend through early detection and curative surgery, approximately 50 000 deaths from gastric cancer occurred in Japan in 1997 [1] . Although patients with metastatic and recurrent gastric cancer still have a poor prognosis, no standard chemotherapy regimen has been established, even as the first-line.
Paclitaxel is an antitumor agent active against various kinds of malignancies. Because paclitaxel is known to be a cell-cycle-specific agent [2, 3] , basic research has suggested that prolongation of exposure might enhance its cytotoxic effects. In a phase I study of weekly paclitaxel, a regimen of 80 mg/m 2 in a 3-weeks-on and 1-week-off schedule was recommended [4] . In this phase I study, a weekly paclitaxel regimen (1-h infusion) produced objective tumor regression in patients previously treated with paclitaxel on a once-every-3-weeks schedule. Recently, successful results have been achieved using a regimen of weekly paclitaxel in patients with breast cancer and ovarian cancer. Hematological toxicity caused by a weekly 3-h infusion schedule has been reported to be milder, with equivalent activity, compared with a schedule of one 24-h infusion every 3 weeks [5] .
Paclitaxel is recognized as one of the active cytotoxic agents for gastric cancer [6] [7] [8] [9] . A weekly paclitaxel regimen has become popular in Japan, mainly as secondline chemotherapy, because of its milder hematological toxicity compared with a once every 3 weeks schedule of paclitaxel. However, only a few trials of weekly paclitaxel in patients with gastric cancer have been reported [10, 11] . In the present retrospective study, we investigated the potential and safety of this more dosedense weekly paclitaxel regimen in patients with pretreated gastric cancer.
Abstract
Background. Paclitaxel scheduled every 3 weeks has shown a response rate of ~20% for gastric cancer, with modest hematological toxicity. Weekly administration of paclitaxel in patients with breast or ovarian cancer has shown equivalent efficacy and milder toxicity compared with an every-3 week schedule. We investigated, retrospectively, the antitumor effects and toxicity profiles of weekly paclitaxel for patients with metastatic or recurrent gastric cancer in clinical practice. 
Patients and methods

Patients
The subjects of this study consisted of 38 patients with metastatic or recurrent gastric cancer treated weekly with paclitaxel between September 2002 and September 2004 at the Shizuoka Cancer Center, Shizuoka, Japan. The recruitment criteria were as follows: (1) histologically proven adenocarcinoma of the stomach; (2) history of one prior chemotherapy regimen not involving paclitaxel or docetaxel; (3) age, 75 years or less; (4) performance status of 2 or less on the Eastern Cooperative Oncology Group scale; (5) adequate bone marrow, hepatic, and renal functions; (6) no other serious disease; (7) and oral or written informed consent given before the commencement of treatment.
Treatment methods
The treatment schedule comprised an intravenous infusion of paclitaxel at 80 mg/m 2 in 250 ml normal saline over 1 h, repeated weekly three times for 4 weeks. Short-term premedication for paclitaxel-associated hypersensitivity reactions was used: dexamethasone, 8 mg; diphenhydramine, 50 mg; ranitidine, 50 mg; and granisetron, 3 mg were administered 30 min before the paclitaxel treatment. This treatment was repeated until disease progression or prohibitive toxicity, usually on an outpatient basis. In the event of serious hematological toxicity, treatment was suspended until recovery. If grade 4 hematological or grade 3 or 4 nonhematological toxicity occurred, the dose of paclitaxel was reduced to 60 mg/m 2 .
Response and toxicity assessments
Tumor measurements for response assessment in patients with primary lesions were made every 1 to 2 months by computed tomography (CT) and endoscopy. Objective responses in measurable metastatic lesions were evaluated according to the response evaluation criteria for solid tumors [12] . Survival time was calculated from the date of the commencement of paclitaxel treatment to the date of death or the last confirmation of survival. Symptomatic toxicity and laboratory data were monitored every week at the outpatient clinic. Toxicity was evaluated according to the National Cancer Institute common toxicity criteria (version 2).
Results
Patient population
Of 51 patients with advanced or recurrent gastric cancer treated with weekly paclitaxel as second-line chemotherapy, 38 patients fulfilled the recruitment criteria, and were included in this study. The 13 excluded patients had severe medical complications: 4 patients were aged 76 years or more, and 9 were performance status 3 or more.
Patient characteristics are presented in Table 1 . Most (63%) were male, and the median age was 63 years. Twenty seven (71%) had a performance status of 0 or 1. All patients had had prior fluorouracil-based chemotherapy as first-line chemotherapy. Seven patients had pleural effusion and 21 had ascites. The number of metastatic organs (including liver, lymph node [LN], peritoneum, lung and bone), was one organ in 15 patients, two organs in 14 patients, and three organs or more in 9 patients.
Dose intensity
The total number of administrations of paclitaxel was 364. The median number of courses per patient was 6 (range, 1-44+). Dose intensity was calculated as 55 mg/m 2 per week, which corresponded to 92% of the planned dose. This treatment was stopped in 35 patients, because of disease progression in 31 patients, 
Toxicity
Toxicity data are presented in Table 2 . Of hematological toxicities, 11 patients (29%) experienced leukopenia of grade 3 or 4 and 12 (32%) had neutropenia of grade 3 or 4. Of nonhematological toxicities, 1 patient (3%) had grade 3 nausea and anorexia. Severe neuropathy was seen in 1 patient (3%) and no allergic reaction was seen in any patient. Seven patients (18%) died within 30 days of the last administration of paclitaxel. The reasons for these early deaths were disease progression in 3 patients; death of other causes (acute myocardial infarction in 1 and heart failure in 1); perforation of the esophagus in 1 (due to an inserted expandable metallic stent for esophageal stenosis caused by mediastinal lymph-node metastasis); and sepsis with grade 4 neutropenia in 1.
Responses and survival
Twenty-five of the 38 patients were assessable for response (13 patients did not have measurable disease). Of these 25 patients, 6 (24%) experienced a partial response ( Table 3 ). The details of the responders are shown in Table 4 . Pleural effusion disappeared in 2 of 7 patients (29%) and decreased in 1 of 7 patients (14%) after treatment with paclitaxel. Ascites disappeared in 3 of 21 patients (14%) and decreased in 2 of 21 patients (10%). The median follow-up period was 260 days. Survival data were updated in February 2005. The median survival time was 151 days after the initiation of weekly paclitaxel therapy (Fig. 1) . The median time to progression was 64 days (Fig. 2) . Twenty-one patients (55%) had no further chemotherapy after disease progression following paclitaxel therapy. Nine patients had irinotecan-containing regimens, 2 had a 5-fluorouracil (5-FU)-based regimen, 1 had intraperitoneal administration of cisplatin (CDDP), and 1 had palliative radiation therapy at the primary site.
Discussion
Recently, weekly paclitaxel has been commonly used in second-line or higher chemotherapy. In the present retrospective study, all 38 patients had a history of prior chemotherapy at our institution. Moreover, 9 patients (24%) had three involved metastatic sites, and 4 (11%) had bone metastases. Seven patients had pleural effusion and 21 had ascites. To clarify the activity and toxicity of paclitaxel as second-line chemotherapy in a clinical practice setting, the recruitment criteria for this study allowed patients to have pleural effusion and/or ascites. We found weekly paclitaxel therapy to be well tolerated by most patients, considering the dose intensity used and its toxicity profile. Previous reports showed that grade 3 or 4 neutropenia occurred in 37%, and grade 4 neutropenia in 67% of patients treated with paclitaxel on an every-3-weeks regimen [7, 9] . In our study, 29% and 32% of patients had severe leukopenia and severe neutropenia, respectively. On the basis of these results, a weekly regimen of paclitaxel seems to be less toxic than an every-3-weeks regimen in terms of hematological toxicity. Furthermore, nonhematological toxicities were generally mild. Seven patients died within 30 days of the last administration of paclitaxel. The causes of the deaths in our study were disease progression in three patients, other medical diseases in two patients, complications due to a metallic stent in one, and treatment-related sepsis in one. These patients had had a severe medical condition or poor oral intake and poor performance status at the last administration of paclitaxel. Therefore, we have to take care regarding the patient's condition and consider cautiously the indications for the administration of paclitaxel.
With weekly paclitaxel therapy, we observed a response rate of 24% in 25 patients with measurable metastatic lesions. Disease stabilization was observed in 40% (10/25). Ascites and pleural effusion decreased or disappeared in 24% (5/21) and 43% (3/7), respectively. Direct comparison of response rates from one trial to another is inherently difficult, given that studies often differ with respect to entry criteria and population char- [6] [7] [8] [9] . Therefore, our response results are within the range observed in other trials, of paclitaxel given every 3 weeks.
On the basis of previously reported data, the median survival time for metastatic or recurrent gastric cancer is about 7 to 9 months [13] [14] [15] [16] [17] with first-line chemotherapy. In the present retrospective study, the median overall survival time after the administration of paclitaxel was about 5 months. These data are the same as the previously reported data [10] for weekly paclitaxel. Our results suggest that weekly paclitaxel may have similar activity to paclitaxel given on a 3-week schedule for patients with metastatic or recurrent gastric cancer after prior therapy.
In conclusion, weekly paclitaxel as second-line chemotherapy was tolerated and demonstrated activity against metastatic and recurrent gastric cancer. How- ever, its administration in practice must be decided with caution in patients in poor condition. The Japan Clinical Oncology Group (JCOG) is now conducting a randomized phase II trial of weekly paclitaxel versus best available 5-FU for second-line chemotherapy for gastric cancer with peritoneal dissemination.
